All In Biotech

Drug Trial Radar · NCT07227285

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Apr 2031

Study completion Apr 2031

Sponsor

Lead sponsor
Cyllene TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

Conditions

  • Urinary Bladder, Overactive
  • Spinal Cord Injury

Interventions

  • UrodynamicsOther

    standardized local evaluation of urodynamic parameters

  • EG110ADrug

    Patients already treated with EG110A

  • Patient-reported OutcomeOther

    assessment of participant's perception of the level of impairment in functioning and well-being associated with NDO symptoms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent serious adverse events (TESAEs)Time frame: 5 years
  2. Incidence of treatment emergent adverse events (TEAEs) including treatment emergent averse events of special interest (TEAESIs)Time frame: 5 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Rancho Los Amigos National Rehabilitation Center

    Downey, California

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

  • Sidney Kimmel Medical College

    Philadelphia, Pennsylvania

  • UTHealth Houston / TIRR Memorial Hermann

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.